Navigation Links
Protein suppresses allergic response in mice
Date:11/19/2007

A protein in mice known as RGS13 suppresses allergic reactions, including the severe, life-threatening allergic reaction known as anaphylaxis, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Because RGS13 is also a protein found in humans and is expressed in only a limited number of cellsincluding the immune systems mast cells that are central to allergic reactionsscientists believe the protein may be an attractive target for developing new drugs to treat and prevent certain allergic reactions, including anaphylaxis.

We still do not know what triggers the allergic or anaphylactic reaction in some people, says NIAID Director Anthony S. Fauci, M.D. These findings open up important research avenues, such as examining the role of RGS13 protein in humans to determine if its deficiency or abnormal function triggers the mast cells to release chemicals that cause allergic diseases.

The research, led by Kirk M. Druey, M.D., senior investigator, at the Laboratory of Allergic Diseases at NIAID, is described in a report online in Nature Immunology.

RGS13 is one of a large group of regulator of G protein signaling (RGS) proteins that act as traffic lights for signaling networks within cells. Though the biochemical actions of most RGS proteins in laboratory tests are known, their physiological functions in the body are still a mystery. Therefore, the current findings may have broader implications for many different biological processes, such as metabolism, cancer progression, cardiac function and others.

Mast cells serve an important role in normal immune function, but little is known about what triggers these cells to sometimes become overactive and cause allergic reactions. The severity of an allergic reaction depends on the quantity of chemicals (histamines, prostaglandins and leukotrienes) released by mast cells. Serious, quick-onset allergic reactions affect
'/>"/>

Contact: Sitara Maruf
marufs@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...be held on January 8, 2009 , , TORONTO, Nov...nal Inc. ("MedEmerg") (OTCBB: MDER), one of Canada... today that it has obtained an interim order from ...ts previously announced plan of arrangement (the "...nc. ("AIM") will acquire all of MedEmerg,s outstan...
(Date:11/21/2008)...ty of Texas Health Science Center at Houston will ... Studies (TEXAS), to promote geriatrics training f...rd from the Donald W. Reynolds Foundation and $1.2... to teach geriatric medicine principles to everyon...ng physicians. With the reach of Lyndon B. Johnson...
(Date:11/21/2008)...e-FirstCall/ -- Heska Corporation,(Nasdaq: HSKA... Society of,Security Analysts, 12th Annual Biotec...2008 at 1177 Avenue of the Americas, 2nd Floor in ...gin at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain...for two weeks,following the presentation through ...
(Date:11/21/2008)...-USNewswire/ -- The Generic,Pharmaceutical Associ...y from,GPhA President and CEO Kathleen Jaeger reg...ble on "Emerging Health Care Competition and Consu...is conducting this roundtable demonstrates the,gr... access to safe and,affordable biogenerics sooner...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2
...done in Greece to show the relationship of the pla...some interesting results.// The study took into co...plains and those living in the hills, data taken i... years, especially concerned with coronary disease...
...nity may lead you to blindness. According to a new...//scientists had been able to find out a genetic c...h of what is commonly known as blindness due to ag... that may cause macular degeneration in elderly pe...
...been successful in developing a computer aided ale...is in patients. //There had not been much attempts...t innovation is one of the first of its kind. The ...tion may be able to reduce the frequency of the co...
... that the drug Rimonabant (Acomplia) a selective ... patients keep weight off // . Supplementation wit...significant decrease in body weight and waist circ...us visceral fat. It also improved HDL (good) chole...
Other Medicine News:
(Date:11/21/2008)... THOUSAND OAKS, Calif., Nov. 21 /PRNewswire-First...that the European Committee for Medicinal,Product...on recommending,marketing authorisation for Nplat...The CHMP recommends Nplate for adult chronic immun...enectomised patients who are refractory to,other ...
(Date:11/20/2008)... SAN MARINO, Calif., Nov. 20 Epei... Phase I/II and II studies of Rexin-G in,chemothe...osteosarcoma, as,presented by Dr. Sant P. Chawla,...meetings held in London UK on November 13-15, 2008... i.v. over a period up to 9 months. Analysis of,s...
(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /P...K ) today announced that the United States Food an...proval for PROMACTA(R) (eltrombopag) for the treat...immune (idiopathic) thrombocytopenic purpura (ITP)...teroids, immunoglobulins or splenectomy. The appro...
(Date:11/20/2008)... RIVERSIDE, Calif., Nov. 20 Milk....better than originally thought. After years of,re...vered peptides found in,cow,s milk that stimulate..., To view the Multimedia News Release, go to:... , , While developing new cancer therapi...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2NYU American Museum of Natural History receive 241 6 million NSF grant 4686 1NYU American Museum of Natural History receive 241 6 million NSF grant 4686 2Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN 28R 29 7451 1Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN 28R 29 7451 2Unexplored Arctic region to be mapped 4685 1GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza 28R 29 7448 1GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza 28R 29 7448 2GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza 28R 29 7448 3GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza 28R 29 7448 4
...MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new...al of Child Neurology indicates,that a treatment f...children with cerebral palsy improves their qualit...established cost-effective,treatments. The finding...access to the treatment, known as Medtronic ITB Th...
...Two anti-aging preventative medicine doctors say t...their advocacy of prescribing,human growth hormone...th aging., DAYTONA BEACH, Fla., April 27, 2007 /PR... (HGH) was at the center of a recent New,York Time...my of,Anti-Aging Medicine (<a target="_blank" href...
Other Medicine Technology:Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 2Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 3Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 4Doctors Outraged Over Growth Hormone Controversy 2
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended.
Sheath Introducers with guidewires.
The Driver Stent design, utilizing an advanced cobalt-based alloy, surpasses the limitations of stainless steel stents. This stronger alloy makes possible thinner struts, for unparalleled flexibility
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner.
Medicine Products: